T
Timothy L. Ratliff
Researcher at Purdue University
Publications - 312
Citations - 20541
Timothy L. Ratliff is an academic researcher from Purdue University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 69, co-authored 306 publications receiving 19092 citations. Previous affiliations of Timothy L. Ratliff include University of Iowa Hospitals and Clinics & Beth Israel Deaconess Medical Center.
Papers
More filters
Patent
Multivalent fibronectin-integrin binding compositions and methods of use thereof
TL;DR: In this article, the authors provide multivalent fibronectin-integrin binding compositions and methods of use thereof and in certain embodiments, the invention provides peptide compositions that include at least two binding peptides coupled together as a cancer therapeutic or a diagnostic tool.
PAGER: constructing PAGs and new PAG-PAG relationships for network biology
Zongliang Yue,Madhura M. Kshirsagar,Thanh Nguyen,Chayaporn Suphavilai,Michael T. Neylon,Liugen Zhu,Timothy L. Ratliff,Jake Y. Chen +7 more
TL;DR: The PAGER database as mentioned in this paper ) is a database for integrating gene set, net15 work, and pathway analysis with a three-letter-code standard naming convention, which includes gene sets, annotated list, and gene-sets (PAGs).
Book ChapterDOI
Chapter 58 – Are Vaccinations for Prostate Cancer Realistic?
TL;DR: The exact role that immunotherapy will have in the management of prostate cancer is yet to be defined and will remain that way for the near future given the time required to complete phase III trials for this disease.
Journal ArticleDOI
Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity.
Ryan D. Calvert,James C. Fleet,Pierrick G.J. Fournier,Patricia Juárez,Grant N. Burcham,Jessica M. Haverkamp,Theresa A. Guise,Timothy L. Ratliff,Bennett D. Elzey +8 more
TL;DR: In this article , the authors found that tumor MDSCs are more differentiated and mature, and that they are morphologically, genetically, and functionally distinct from spleen and BM M-MDSCs.
Posted ContentDOI
TNF Blockade Reduces Prostatic Hyperplasia and Inflammation while Limiting BPH Diagnosis in Patients with Autoimmune Disease
Renee E. Vickman,Aaron-Brooks L,Aaron-Brooks L,Renyuan Zhang,Nadia A. Lanman,Brittany Lapin,Gil,Greenberg M,Takeshi Sasaki,Gregory M. Cresswell,Meaghan M. Broman,Jacqueline Petkewicz,Pooja Talaty,Brian T. Helfand,Alexander P. Glaser,Chi-Hsiung Wang,Omar E. Franco,Omar E. Franco,Timothy L. Ratliff,Kent L. Nastiuk,Susan E. Crawford,Susan E. Crawford,Simon W. Hayward,Simon W. Hayward +23 more
TL;DR: In this article, the tumor necrosis factor (TNF)α-antagonist etanercept was tested in two murine models of prostatic enlargement to determine if AI disease correlates with BPH diagnosis and whether systemic targeting of an inflammatory mediator limits prostatic inflammation and hyperplasia.